Galapagos (NASDAQ:GLPG) Hits New 52-Week Low – Time to Sell?

Shares of Galapagos NV (NASDAQ:GLPG) reached a new 52-week low during trading on Monday . The stock traded as low as $22.36 and last traded at $22.51, with a volume of 26245 shares. The stock had previously closed at $22.78.

Analyst Ratings Changes

Several research firms recently commented on GLPG. TD Cowen lowered shares of Galapagos from a “strong-buy” rating to a “strong sell” rating in a report on Thursday, January 9th. Royal Bank of Canada reduced their price objective on Galapagos from $32.00 to $30.00 and set a “sector perform” rating on the stock in a research note on Friday, November 1st. Barclays restated an “underweight” rating on shares of Galapagos in a report on Thursday, January 23rd. Finally, Kepler Capital Markets cut Galapagos from a “hold” rating to a “reduce” rating in a research note on Wednesday, November 20th. Four analysts have rated the stock with a sell rating and six have assigned a hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $30.75.

Galapagos Trading Up 0.2 %

The business has a 50-day simple moving average of $25.76 and a 200 day simple moving average of $27.15.

Institutional Trading of Galapagos

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GLPG. Creative Planning purchased a new stake in shares of Galapagos in the 2nd quarter worth about $456,000. GAMMA Investing LLC raised its stake in Galapagos by 77.4% in the fourth quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company’s stock worth $61,000 after buying an additional 974 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new stake in Galapagos in the third quarter worth about $1,077,000. Signaturefd LLC boosted its position in Galapagos by 65.6% during the 3rd quarter. Signaturefd LLC now owns 6,413 shares of the biotechnology company’s stock valued at $185,000 after acquiring an additional 2,541 shares in the last quarter. Finally, R Squared Ltd purchased a new position in shares of Galapagos during the 4th quarter worth approximately $26,000. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.